The role of complement regulatory proteins in peripheral blood cells of patients with systemic lupus erythematosus: Review

Cellular Immunology

Volumn 277, Issue 1-2, 2012, Pages 1-7

  Alegretti, Ana Paula ^a   Schneider, Laiana ^a   Piccoli, Amanda Kirchner ^a   Xavier, Ricardo Machado ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

CD35; CD46; CD55; CD59; Complement; Systemic lupus erythematosus (SLE)

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

CELL PROTECTION; CELLULAR IMMUNITY; CYTOPENIA; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; BLOOD CELLS; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 84864299072     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.06.008     Document Type: Review

References (78)

1. Wagner E., Frank M.M. Therapeutic potential of complement modulation. Nat. Rev. Drug Discov. 2010, 9:43-56.
2. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058-1066.
3. Ogden C.A., Elkon K.B. Role of complement and other innate immune mechanisms in the removal of apoptotic cells. Curr. Dir. Autoimmun. 2006, 9:120-142.
4. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010, 20:34-50.
5. Fang C., Miwa T., Shen H., Song W.C. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J. Immunol. 2007, 179:3178-3186.
6. Carroll M.C. The role of complement in B cell activation and tolerance. Adv. Immunol. 2000, 74:61-88.
7. Welch T.R. Complement in glomerulonephritis. Nat. Genet. 2002, 31:333-334.
8. Schumaker V.N., Zavodszky P., Poon P.H. Activation of the first component of complement. Annu. Rev. Immunol. 1987, 5:21-42.
9. Gewurz H., Ying S.C., Jiang H., Lint T.F. Nonimmune activation of the classical complement pathway. Behring Inst. Mitt. 1993, 138-147.
10. Farries T.C., Lachmann P.J., Harrison R.A. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochem. J. 1988, 252:47-54.
11. Gupta R., Ahuja T., Agraharkar M. Disorders of the complement system: an overview. Saudi J. Kidney Dis. Transpl. 2002, 13:119-125.
12. Monticielo O.A., Mucenic T., Xavier R.M., Brenol J.C., Chies J.A. The role of mannose-binding lectin in systemic lupus erythematosus. Clin. Rheumatol. 2008, 27:413-419.
13. Dahl M.R., Thiel S., Matsushita M., Fujita T., Willis A.C., Christensen T., Vorup-Jensen T., Jensenius J.C. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15:127-135.
14. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009, 9:729-740.
15. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
16. Morgan B.P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 1989, 264:1-14.
17. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008, 6:132-142.
18. Song W.C., Sarrias M.R., Lambris J.D. Complement and innate immunity. Immunopharmacology 2000, 49:187-198.
19. Walport M.J. Complement. Second of two parts. N. Engl. J. Med. 2001, 344:1140-1144.
20. Kimberley F.C., Sivasankar B. Paul Morgan B. Alternative roles for CD59. Mol. Immunol. 2007, 44:73-81.
21. Lublin D.M., Atkinson J.P. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 1989, 7:35-58.
22. Farkas I., Baranyi L., Ishikawa Y., Okada N., Bohata C., Budai D., Fukuda A., Imai M., Okada H. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9. J. Physiol. 2002, 539:537-545.
23. Kim D.D., Song W.C. Membrane complement regulatory proteins. Clin. Immunol. 2006, 118:127-136.
24. Medof M.E., Walter E.I., Rutgers J.L., Knowles D.M., Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 1987, 165:848-864.
25. Heeger P.S., Lalli P.N., Lin F., Valujskikh A., Liu J., Muqim N., Xu Y., Medof M.E. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 2005, 201:1523-1530.
26. Finberg R.W., White W., Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J. Immunol. 1992, 149:2055-2060.
27. Hamann J., Vogel B., van Schijndel G.M., van Lier R.A. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J. Exp. Med. 1996, 184:1185-1189.
28. Pham T., Kaul A., Hart A., Goluszko P., Moulds J., Nowicki S., Lublin D.M., Nowicki B.J. Dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor. Infect. Immun. 1995, 63:1663-1668.
29. Deckert M., Kubar J., Bernard A. CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation. J. Immunol. 1992, 148:672-677.
30. van den Berg C.W., Cinek T., Hallett M.B., Horejsi V., Morgan B.P. Exogenous glycosyl phosphatidylinositol-anchored CD59 associates with kinases in membrane clusters on U937 cells and becomes Ca(2+)-signaling competent. J. Cell Biol. 1995, 131:669-677.
31. Monleon I., Martinez-Lorenzo M.J., Anel A., Lasierra P., Larrad L., Pineiro A., Naval J., Alava M.A. CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells. Eur. J. Immunol. 2000, 30:1078-1087.
32. Omidvar N., Wang E.C., Brennan P., Longhi M.P., Smith R.A., Morgan B.P. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. J. Immunol. 2006, 176:2915-2923.
33. Erdei A., Prechl J., Isaak A., Molnar E. Regulation of B-cell activation by complement receptors CD21 and CD35. Curr. Pharm. Des. 2003, 9:1849-1860.
34. Krych-Goldberg M., Atkinson J.P. Structure-function relationships of complement receptor type 1. Immunol. Rev. 2001, 180:112-122.
35. Khera R., Das N. Complement receptor 1: disease associations and therapeutic implications. Mol. Immunol. 2009, 46:761-772.
36. Roozendaal R., Carroll M.C. Complement receptors CD21 and CD35 in humoral immunity. Immunol. Rev. 2007, 219:157-166.
37. Krych-Goldberg M., Hauhart R.E., Subramanian V.B., Yurcisin B.M., Crimmins D.L., Hourcade D.E., Atkinson J.P. Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases. J. Biol. Chem. 1999, 274:31160-31168.
38. Cardone J., Le Friec G., Vantourout P., Roberts A., Fuchs A., Jackson I., Suddason T., Lord G., Atkinson J.P., Cope A., Hayday A., Kemper C. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 2010, 11:862-871.
39. Barchet W., Price J.D., Cella M., Colonna M., MacMillan S.K., Cobb J.P., Thompson P.A., Murphy K.M., Atkinson J.P., Kemper C. Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation. Blood 2006, 107:1497-1504.
40. Giannakis E., Jokiranta T.S., Ormsby R.J., Duthy T.G., Male D.A., Christiansen D., Fischetti V.A., Bagley C., Loveland B.E., Gordon D.L. Identification of the streptococcal M protein binding site on membrane cofactor protein (CD46). J. Immunol. 2002, 168:4585-4592.
41. Kallstrom H., Blackmer Gill D., Albiger B., Liszewski M.K., Atkinson J.P., Jonsson A.B. Attachment of Neisseria gonorrhoeae to the cellular pilus receptor CD46: identification of domains important for bacterial adherence. Cell. Microbiol. 2001, 3:133-143.
42. Mori Y., Yang X., Akkapaiboon P., Okuno T., Yamanishi K. Human herpesvirus 6 variant A glycoprotein H-glycoprotein L-glycoprotein Q complex associates with human CD46. J. Virol. 2003, 77:4992-4999.
43. Riley-Vargas R.C., Gill D.B., Kemper C., Liszewski M.K., Atkinson J.P. CD46: expanding beyond complement regulation. Trends Immunol. 2004, 25:496-503.
44. Oelschlaegel U., Besson I., Arnoulet C., Sainty D., Nowak R., Naumann R., Bux Y., Ehninger G. A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. Clin. Lab Haematol. 2001, 23:81-90.
45. Meletis J., Terpos E., Samarkos M., Meletis C., Konstantopoulos K., Komninaka V., Apostolidou E., Benopoulou O., Korovesis K., Mavrogianni D., Variami E., Yataganas X., Loukopoulos D. Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders. Haematologia (Budap) 2001, 31:7-16.
46. Azenishi Y., Ueda E., Machii T., Nishimura J., Hirota T., Shibano M., Nakao S., Kinoshita T., Mizoguchi H., Kitani T. CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anaemia. Br. J. Haematol. 1999, 104:523-529.
47. Kaminski H.J., Kusner L.L., Richmonds C., Medof M.E., Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp. Neurol. 2006, 202:287-293.
48. Meletis J., Terpos E., Samarkos M., Meletis C., Apostolidou E., Komninaka V., Korovesis K., Anargyrou K., Benopoulou O., Mavrogianni D., Variami E., Viniou N., Konstantopoulos K. Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias. Int. J. Hematol. 2002, 75:40-44.
49. Meletis J., Terpos E., Samarkos M., Meletis C., Apostolidou E., Komninaka V., Korovesis K., Mavrogianni D., Boutsis D., Variami E., Viniou N., Konstantopoulos K., Loukopoulos D. Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes. Hematol. J. 2001, 2:33-37.
50. Ruiz P., Weppler D., Tryphonopoulos P., Nishida S., Moon J., Kato T., Selvaggi G., Levi D., Madariaga J., DelaGarza J., Tuteja S., Garcia M., Tzakis A. CD55 and CD59 deficiency in transplant patient populations: possible association with paroxysmal nocturnal hemoglobinuria-like symptoms in Campath-treated patients. Transplant. Proc. 2006, 38:1750-1752.
51. Sugimori C., Chuhjo T., Feng X., Yamazaki H., Takami A., Teramura M., Mizoguchi H., Omine M., Nakao S. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006, 107:1308-1314.
52. Yang L.B., Li R., Meri S., Rogers J., Shen Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 2000, 20:7505-7509.
53. Yamaguchi M., Machii T., Azenishi Y., Nishimura J., Shibano M., Kanakura Y., Kitani T. Detection of small populations of CD59-deficient erythrocytes in patients with aplastic anemia or myelodysplastic syndrome and normal individuals. Blood Cells Mol. Dis. 2000, 26:247-254.
54. Wang H., Chuhjo T., Yamazaki H., Shiobara S., Teramura M., Mizoguchi H., Nakao S. Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur. J. Haematol. 2001, 66:200-205.
55. Hu R., Mukhina G.L., Piantadosi S., Barber J.P., Jones R.J., Brodsky R.A. PIG-A mutations in normal hematopoiesis. Blood 2005, 105:3848-3854.
56. D'Cruz D.P., Khamashta M.A., Hughes G.R. Systemic lupus erythematosus. Lancet 2007, 369:587-596.
57. Munoz L.E., Lauber K., Schiller M., Manfredi A.A., Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 2010, 6:280-289.
58. Leers M.P., Bjorklund V., Bjorklund B., Jornvall H., Nap M. An immunohistochemical study of the clearance of apoptotic cellular fragments. Cell. Mol. Life Sci. 2002, 59:1358-1365.
59. Nauta A.J., Raaschou-Jensen N., Roos A., Daha M.R., Madsen H.O., Borrias-Essers M.C., Ryder L.P., Koch C., Garred P. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur. J. Immunol. 2003, 33:2853-2863.
60. Ferreira V.P., Pangburn M.K., Cortes C. Complement control protein factor H: the good, the bad, and the inadequate. Mol. Immunol. 2010, 47:2187-2197.
61. Hepburn A.L., Narat S., Mason J.C. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford) 2010, 49:2243-2254.
62. Voulgarelis M., Kokori S.I., Ioannidis J.P., Tzioufas A.G., Kyriaki D., Moutsopoulos H.M. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann. Rheum. Dis. 2000, 59:217-222.
63. Morimoto C., Schlossman S.F. Antilymphocyte antibodies and systemic lupus erythematosus. Arthritis Rheum. 1987, 30:225-228.
64. Nossent J.C., Swaak A.J. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q. J. Med. 1991, 80:605-612.
65. Garcia-Valladares I., Atisha-Fregoso Y., Richaud-Patin Y., Jakez-Ocampo J., Soto-Vega E., Elias-Lopez D., Carrillo-Maravilla E., Cabiedes J., Ruiz-Arguelles A., Llorente L. Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia. Lupus 2006, 15:600-605.
66. Alegretti A.P., Mucenic T., Merzoni J., Faulhaber G.A., Silla L.M., Xavier R.M. Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients. Cell. Immunol. 2010, 265:127-132.
67. Richaud-Patin Y., Perez-Romano B., Carrillo-Maravilla E., Rodriguez A.B., Simon A.J., Cabiedes J., Jakez-Ocampo J., Llorente L., Ruiz-Arguelles A. Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunol. Lett. 2003, 88:95-99.
68. A.P. Alegretti, T. Mucenic, J.C. Brenol, R.M. Xavier R. O papel das proteínas reguladoras do complemento CD55/CD59 em células de sangue periférico de pacientes com lúpus eritematoso sistêmico. Rev Bras Reumatol (2009) 276-287.
69. Ruiz-Arguelles A., Llorente L. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun. Rev. 2007, 6:155-161.
70. Miwa T., Maldonado M.A., Zhou L., Sun X., Luo H.Y., Cai D., Werth V.P., Madaio M.P., Eisenberg R.A., Song W.C. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am. J. Pathol. 2002, 161:1077-1086.
71. Cohen J.H., Lutz H.U., Pennaforte J.L., Bouchard A., Kazatchkine M.D. Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 1992, 87:422-428.
72. Cornillet P., Gredy P., Pennaforte J.L., Meyer O., Kazatchkine M.D., Cohen J.H. Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 1992, 89:22-25.
73. Lach-Trifilieff E., Marfurt J., Schwarz S., Sadallah S., Schifferli J.A. Complement receptor 1 (CD35) on human reticulocytes: normal expression in systemic lupus erythematosus and HIV-infected patients. J. Immunol. 1999, 162:7549-7554.
74. Arora M., Arora R., Tiwari S.C., Das N., Srivastava L.M. Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus 2000, 9:127-131.
75. Arora V., Mondal A.M., Grover R., Kumar A., Chattopadhyay P., Das N. Modulation of CR1 transcript in systemic lupus erythematosus (SLE) by IFN-gamma and immune complex. Mol. Immunol. 2007, 44:1722-1728.
76. Birmingham D.J., Gavit K.F., McCarty S.M., Yu C.Y., Rovin B.H., Nagaraja H.N., Hebert L.A. Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin. Exp. Immunol. 2006, 143:274-280.
77. Endoh M., Yamashina M., Ohi H., Funahashi K., Ikuno T., Yasugi T., Atkinson J.P., Okada H. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin. Exp. Immunol. 1993, 94:182-188.
78. Kawano M., Seya T., Koni I., Mabuchi H. Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 1999, 116:542-546.